Your browser doesn't support javascript.
loading
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
Roberts, Matthew A; Huang, Louis; Lee, Darren; MacGinley, Robert; Troster, Stefanie M A; Kent, Annette B; Bansal, Sukhvinder S; Macdougall, Iain C; McMahon, Lawrence P.
Afiliação
  • Roberts MA; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
  • Huang L; Department of Renal Medicine, Eastern Health, Box Hill, VIC, Australia.
  • Lee D; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
  • MacGinley R; Department of Renal Medicine, Eastern Health, Box Hill, VIC, Australia.
  • Troster SM; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
  • Kent AB; Department of Renal Medicine, Eastern Health, Box Hill, VIC, Australia.
  • Bansal SS; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
  • Macdougall IC; Department of Renal Medicine, Eastern Health, Box Hill, VIC, Australia.
  • McMahon LP; Department of Renal Medicine, Eastern Health, Box Hill, VIC, Australia.
BMC Nephrol ; 17(1): 177, 2016 11 16.
Article em En | MEDLINE | ID: mdl-27852236
BACKGROUND: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. METHODS: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS). The primary outcome was change in iFGF23 and cFGF23 from pre-infusion to Day 2 post-infusion. Serum hepcidin, ferritin and phosphate were also measured. Pair-wise comparisons utilised the Wilcoxon rank sum test; linear mixed models with an interaction term for treatment and time evaluated between-group effects. RESULTS: Forty-two participants completed the study. In those randomized to FCM (n = 22), median (interquartile range) values pre-infusion and Day 2, respectively, were 843 pg/mL (313-1922) and 576 pg/mL (356-1296, p = 0.05) for iFGF23, 704RU/mL (475-1204) and 813RU/mL (267-1156, p = 0.04) for cFGF23, and 1.53 mmol/L (1.14-1.71) and 1.37 (1.05-1.67, p = 0.03) for phosphate. These parameters did not change following IS. Both serum ferritin (p < 0.001) and hepcidin (p < 0.001) increased in both groups, and the increase in hepcidin was greater in the FCM group (p = 0.03 for between-group difference). CONCLUSIONS: Contrary to iron-deficient people with normal renal function, haemodialysis patients given protocol-driven intravenous FCM demonstrated a fall in iFGF23 and a rise in cFGF23, changes not evident with IS. This suggests a differential effect of intravenous iron treatment according to both formulation and renal function. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Register ACTRN12614000548639 . Registered 22 May 2014 (retrospectively registered).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Férricos / Insuficiência Renal Crônica / Fatores de Crescimento de Fibroblastos / Ácido Glucárico / Hematínicos / Maltose Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Nephrol Assunto da revista: NEFROLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Férricos / Insuficiência Renal Crônica / Fatores de Crescimento de Fibroblastos / Ácido Glucárico / Hematínicos / Maltose Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Nephrol Assunto da revista: NEFROLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália País de publicação: Reino Unido